Carcinoid Tumor  >>  Imlygic (talimogene laherparepvec)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Imlygic (talimogene laherparepvec) / Amgen
NCT00289016 / 2006-003841-17: A Study of Talimogene Laherparepvec in Stage IIIc and Stage IV Malignant Melanoma

Completed
2
50
US, Europe
Talimogene Laherparepvec, OncoVEX^GM-CSF, T-VEC, IMLYGIC
BioVex Limited, Symbion Research International
Melanoma
12/08
05/09
NCT02574260: An Extension Protocol for the Extended Use of Talimogene Laherparepvec for Eligible Patients Who Participated in Study 002/03 (NCT00289016)

Completed
2
3
NA
Talimogene Laherparepvec, OncoVEX^GM-CSF, T-VEC, IMLYGIC
BioVex Limited, Covance
Melanoma
01/10
01/10

Download Options